Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Cushing Syndrome 2Prostatic Neoplasms 1Pathologic Processes 1Neoplasms 1Hypertension 1Hyperglycemia 1Glucose Intolerance 1Endocrine System Diseases 1Diabetes Mellitus, Type 2 1Adrenocortical Hyperfunction 1Adrenocortical Carcinoma 1Adrenal Gland Diseases 1Adrenal Cortex Neoplasms 1ACTH Syndrome, Ectopic 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × relacorilant × Clear all
NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

University of Chicago

Phase 1 Completed
42 enrolled
Genitourinary

Prostatic Neoplasms

NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

Phase 1 Completed
30 enrolled

Cushing Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡